Pan-European arthritis treatment brief heads to 90TEN Healthcare

90TEN Healthcare has won duties on the two-year rollout of a biopharmaceutical treatment for arthritis across Europe.

90TEN senior account director James Osborn: will lead the account
90TEN senior account director James Osborn: will lead the account

Inflectra is made by pharma company Hospira and is one of the first two examples of a medicine known as a monoclonal-antibody biosimilar.

A biosimilar is a close copy of a biological medicine that has already been authorised for use, in this case Remicade.

The first biosimilar was approved in Europe in 2006. According to the European Medicines Agency, Inflectra is the first time the biosimilar concept has been applied successfully to such a complex molecule as a monoclonal antibody.

Hospira, which awarded the account to 90TEN following a competitive pitch, has done limited comms work on biosimilars in Europe.

Senior account director James Osborn, who will lead the account, said: ‘A vital part of our role will be to drive engagement around how Hospira’s offering can help relieve some of the challenges faced by Europe’s healthcare systems.’

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus

Latest Articles

Max Clifford trial jury finishes sixth day of deliberations

Max Clifford trial jury finishes sixth day of deliberations

The jury in the trial of celebrity publicist Max Clifford on 11 charges of indecent assault has been sent home and will reconvene tomorrow morning for a seventh day of deliberations.

Analysis: Fishburn chiefs keep eyes on future despite mounting departures

Analysis: Fishburn chiefs keep eyes on future despite mounting departures

Fishburn's management have defended their reinvention of the 23-year-old agency amid industry mutterings, fed by a series of director-level departures, about the direction in which it is going.

Hit or Miss? EasyJet backs Shakespeare Day campaign with world record attempt

Hit or Miss? EasyJet backs Shakespeare Day campaign with world record attempt

EasyJet aimed to break the world record for the highest ever theatrical performance for Shakespeare's 450th birthday yesterday with the Reduced Shakespeare Company performing on a flight from Gatwick to Verona.

Top PRs to gather in Barcelona for inaugural PRWeek Global Congress

Top PRs to gather in Barcelona for inaugural PRWeek Global Congress

Senior executives from IBM, Nestlé, Vedanta, GE, Cargill, Philips and Allianz will be among the speakers at PRWeek's first Global Congress.